mTOR Inhibition &amp; Clinical Transplantation: Pancreas &amp; Islet

Berney, Thierry; Andres, Axel; Toso, Christian; Majno, Pietro; Squifflet, Jean-Paul

doi:10.1097/TP.0000000000001700

Scientific article

English

mTOR Inhibition & Clinical Transplantation: Pancreas & Islet

Contributors

Berney, Thierry; Andres, Axel; Toso, Christian

; Majno, Pietro; Squifflet, Jean-Paul

Published in

Transplantation

Publication date

2017

Abstract

This brief overview discusses the beneficial and deleterious effects of mTOR inhibitors on beta-cells, and how sirolimus- and everolimus-based immunosuppression have impacted on practices and outcomes of pancreas and islet transplantation. Sirolimus was the cornerstone of immunosuppressive regimens in islet transplantation at the turn of the millenium, but utilization of mTOR inhibitors has progressively decreased from >80% to <50% of islet transplant recipients in more recent years. For whole pancreas transplantation, mTOR inhibitors were used in approximately 20% of patients in the early 2000s, but this dropped over the years to <10% currently. This decrease is arguably due to less well tolerated side effects without the advantage of better outcomes. Nonetheless, mTOR inhibitors remain extremely valuable as second line immunosuppressants in pancreas and islet transplantation.

UNIGE affiliation entities

Faculté de médecine / Section de médecine clinique / Département de chirurgie

UNIGE research groups

Citation (ISO format)

BERNEY, Thierry et al. mTOR Inhibition & Clinical Transplantation: Pancreas & Islet. In: Transplantation, 2017. doi: 10.1097/TP.0000000000001700

Article (Accepted version)

Identifiers

PID : unige:93702
DOI : 10.1097/TP.0000000000001700
PMID : 28230643

Journal ISSN

0041-1337

479views

0downloads

Creation

02/03/2017 13:59:00

First validation

02/03/2017 13:59:00

Update

13/10/2025 20:03:53

Status update

15/03/2023 01:36:28

Last indexation

04/02/2026 14:49:48